Basic Information
| RNALocate ID: | RLID:11004054 |
| RNA Symbol: | hsa-miR-654-3p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-654-3p |
| RNA ID: | miRBase:MIMAT0004814 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23663360 |
| Tissue/Cell Line: | Plasma |
| Method: | Next-generation RNA sequencing |
| Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID-D:11000210 | Exosome | Endothelial cells | |
| RLID-D:11000708 | Microvesicle | Fibroblasts|Mesenchymal stem cells |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-654-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-65425 |
| MNDR | hsa-miR-654-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-65426 |
| MNDR | hsa-miR-654-3p | Lymphoma | MNDR-E-MI-65427 |
| MNDR | hsa-miR-654-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-65428 |
| MNDR | hsa-miR-654-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-65429 |
| MNDR | hsa-miR-654-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-65430 |
| MNDR | hsa-miR-654-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-65431 |
| MNDR | hsa-miR-654-3p | Her2-receptor positive breast cancer | MNDR-E-MI-65432 |
| MNDR | hsa-miR-654-3p | Alzheimer disease | MNDR-E-MI-65433 |
| MNDR | hsa-miR-654-3p | Bladder cancer | MNDR-E-MI-65434 |
| MNDR | hsa-miR-654-3p | Dysautonomia familial | MNDR-E-MI-65435 |
| MNDR | hsa-miR-654-3p | Seizures | MNDR-E-MI-65436 |
| MNDR | hsa-miR-654-3p | Cardiovascular disease | MNDR-E-MI-65437 |
| MNDR | hsa-miR-654-3p | Lung cancer | MNDR-E-MI-65438 |
| MNDR | hsa-miR-654-3p | Parkinson disease | MNDR-E-MI-65439 |
| MNDR | hsa-miR-654-3p | Breast cancer | MNDR-E-MI-65440 |
| MNDR | hsa-miR-654-3p | Thyroid cancer | MNDR-E-MI-65441 |
| MNDR | hsa-miR-654-3p | Pituitary neoplasms | MNDR-E-MI-65442 |
| MNDR | hsa-miR-654-3p | Pancreatic cancer | MNDR-E-MI-65443 |
| MNDR | hsa-miR-654-3p | Colon adenocarcinoma | MNDR-E-MI-65444 |
| MNDR | hsa-miR-654-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-65445 |
| MNDR | hsa-miR-654-3p | Ovarian cancer | MNDR-E-MI-65446 |
| MNDR | hsa-miR-654-3p | Acromegaly | MNDR-E-MI-65447 |
| MNDR | hsa-miR-654-3p | Prostate adenocarcinoma | MNDR-E-MI-65448 |
| MNDR | hsa-miR-654-3p | Carcinoma ductal breast | MNDR-E-MI-65449 |
| MNDR | hsa-miR-654-3p | Glioblastoma | MNDR-E-MI-65450 |
| MNDR | hsa-miR-654-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-65451 |
| MNDR | hsa-miR-654-3p | Osteosarcoma | MNDR-E-MI-65452 |
| MNDR | hsa-miR-654-3p | Middle cerebral artery infarction | MNDR-E-MI-65453 |
| MNDR | hsa-miR-654-3p | Meningioma | MNDR-E-MI-65454 |
| MNDR | hsa-miR-654-3p | Gastric adenocarcinoma | MNDR-E-MI-65455 |
| MNDR | hsa-miR-654-3p | Cervical squamous cell carcinoma | MNDR-E-MI-65456 |
| MNDR | hsa-miR-654-3p | Bone-invasive pituitary adenoma | MNDR-E-MI-65457 |
| MNDR | hsa-miR-654-3p | Lung adenocarcinoma | MNDR-E-MI-65458 |
| MNDR | hsa-miR-654-3p | Adrenocortical carcinoma | MNDR-E-MI-65459 |
| MNDR | hsa-miR-654-3p | Thyroid carcinoma | MNDR-E-MI-65460 |
| MNDR | hsa-miR-654-3p | Ovarian carcinoma | MNDR-E-MI-65461 |
| MNDR | hsa-miR-654-3p | Bladder urothelial carcinoma | MNDR-E-MI-65462 |
| MNDR | hsa-miR-654-3p | Pancreatic adenocarcinoma | MNDR-E-MI-65463 |
| MNDR | hsa-miR-654-3p | Carcinoma renal cell | MNDR-E-MI-65464 |
| MNDR | hsa-miR-654-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-65465 |
| MNDR | hsa-miR-654-3p | Renal clear cell carcinoma | MNDR-E-MI-65466 |
| MNDR | hsa-miR-654-3p | Lung small cell carcinoma | MNDR-E-MI-65467 |
| MNDR | hsa-miR-654-3p | Synovial sarcoma | MNDR-E-MI-65468 |
| MNDR | hsa-miR-654-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-65469 |
| MNDR | hsa-miR-654-3p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-65470 |
| MNDR | hsa-miR-654-3p | Breast invasive carcinoma | MNDR-E-MI-65471 |
| MNDR | hsa-miR-654-3p | Hepatocellular carcinoma | MNDR-E-MI-65472 |
| MNDR | hsa-miR-654-3p | Rheumatoid arthritis | MNDR-E-MI-65473 |
| MNDR | hsa-miR-654-3p | Colorectal cancer | MNDR-E-MI-65474 |
| MNDR | hsa-miR-654-3p | Stroke lacunar | MNDR-E-MI-65475 |
| MNDR | hsa-miR-654-3p | Breast cancer her3+ negative | MNDR-E-MI-65476 |
| MNDR | hsa-miR-654-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-65477 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | CDKN1A | Homo sapiens | RR00311800 |
TOP